Endothelial function in women of the Kronos Early Estrogen Prevention Study

J. M. Kling, B. A. Lahr, Kent R Bailey, S. M. Harman, Virginia M Miller, S. L. Mulvagh

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective Endothelial dysfunction occurs early in the atherosclerotic disease process, often preceding clinical symptoms. Use of menopausal hormone treatment (MHT) to reduce cardiovascular risk is controversial. This study evaluated effects of 4 years of MHT on endothelial function in healthy, recently menopausal women. Methods Endothelial function was determined by pulse volume digital tonometry providing a reactive hyperemia index (RHI) in a subset of women enrolled in the Kronos Early Estrogen Prevention Study. RHI was measured before and annually after randomization to daily oral conjugated equine estrogen (oCEE, 0.45 mg), weekly transdermal 17β-estradiol (tE2, 50 μg) each with intermittent progesterone (200 mg daily 12 days of the month) or placebo pills and patch. Results At baseline, RHI averaged 2.39 ± 0.69 (mean ± standard deviation; n = 83), and over follow-up did not differ significantly among groups: oCEE, 2.26 ± 0.48 (n = 26); tE2, 2.26 ± 0.45 (n = 24); and placebo, 2.37 ± 0.37 (n = 33). Changes in RHI did not correlate with changes in traditional cardiovascular risk factors, but may inversely correlate with carotid intima medial thickness (Spearman correlation coefficient ρ = -0.268, p = 0.012). Conclusion In this 4-year prospective assessment of recently menopausal women, MHT did not significantly alter RHI when compared to placebo.

Original languageEnglish (US)
Pages (from-to)187-197
Number of pages11
JournalClimacteric
Volume18
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

Hyperemia
Estrogens
Placebos
Hormones
Conjugated (USP) Estrogens
Manometry
Random Allocation
Progesterone
Estradiol
Therapeutics

Keywords

  • Cardiovascular disease
  • carotid intima-medial thickness
  • digital tonometry
  • endothelium
  • estrogen
  • menopausal symptoms

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Endothelial function in women of the Kronos Early Estrogen Prevention Study. / Kling, J. M.; Lahr, B. A.; Bailey, Kent R; Harman, S. M.; Miller, Virginia M; Mulvagh, S. L.

In: Climacteric, Vol. 18, No. 2, 01.04.2015, p. 187-197.

Research output: Contribution to journalArticle

Kling, J. M. ; Lahr, B. A. ; Bailey, Kent R ; Harman, S. M. ; Miller, Virginia M ; Mulvagh, S. L. / Endothelial function in women of the Kronos Early Estrogen Prevention Study. In: Climacteric. 2015 ; Vol. 18, No. 2. pp. 187-197.
@article{3aa768f19c544514beda3450d087e3c6,
title = "Endothelial function in women of the Kronos Early Estrogen Prevention Study",
abstract = "Objective Endothelial dysfunction occurs early in the atherosclerotic disease process, often preceding clinical symptoms. Use of menopausal hormone treatment (MHT) to reduce cardiovascular risk is controversial. This study evaluated effects of 4 years of MHT on endothelial function in healthy, recently menopausal women. Methods Endothelial function was determined by pulse volume digital tonometry providing a reactive hyperemia index (RHI) in a subset of women enrolled in the Kronos Early Estrogen Prevention Study. RHI was measured before and annually after randomization to daily oral conjugated equine estrogen (oCEE, 0.45 mg), weekly transdermal 17β-estradiol (tE2, 50 μg) each with intermittent progesterone (200 mg daily 12 days of the month) or placebo pills and patch. Results At baseline, RHI averaged 2.39 ± 0.69 (mean ± standard deviation; n = 83), and over follow-up did not differ significantly among groups: oCEE, 2.26 ± 0.48 (n = 26); tE2, 2.26 ± 0.45 (n = 24); and placebo, 2.37 ± 0.37 (n = 33). Changes in RHI did not correlate with changes in traditional cardiovascular risk factors, but may inversely correlate with carotid intima medial thickness (Spearman correlation coefficient ρ = -0.268, p = 0.012). Conclusion In this 4-year prospective assessment of recently menopausal women, MHT did not significantly alter RHI when compared to placebo.",
keywords = "Cardiovascular disease, carotid intima-medial thickness, digital tonometry, endothelium, estrogen, menopausal symptoms",
author = "Kling, {J. M.} and Lahr, {B. A.} and Bailey, {Kent R} and Harman, {S. M.} and Miller, {Virginia M} and Mulvagh, {S. L.}",
year = "2015",
month = "4",
day = "1",
doi = "10.3109/13697137.2014.986719",
language = "English (US)",
volume = "18",
pages = "187--197",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Endothelial function in women of the Kronos Early Estrogen Prevention Study

AU - Kling, J. M.

AU - Lahr, B. A.

AU - Bailey, Kent R

AU - Harman, S. M.

AU - Miller, Virginia M

AU - Mulvagh, S. L.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Objective Endothelial dysfunction occurs early in the atherosclerotic disease process, often preceding clinical symptoms. Use of menopausal hormone treatment (MHT) to reduce cardiovascular risk is controversial. This study evaluated effects of 4 years of MHT on endothelial function in healthy, recently menopausal women. Methods Endothelial function was determined by pulse volume digital tonometry providing a reactive hyperemia index (RHI) in a subset of women enrolled in the Kronos Early Estrogen Prevention Study. RHI was measured before and annually after randomization to daily oral conjugated equine estrogen (oCEE, 0.45 mg), weekly transdermal 17β-estradiol (tE2, 50 μg) each with intermittent progesterone (200 mg daily 12 days of the month) or placebo pills and patch. Results At baseline, RHI averaged 2.39 ± 0.69 (mean ± standard deviation; n = 83), and over follow-up did not differ significantly among groups: oCEE, 2.26 ± 0.48 (n = 26); tE2, 2.26 ± 0.45 (n = 24); and placebo, 2.37 ± 0.37 (n = 33). Changes in RHI did not correlate with changes in traditional cardiovascular risk factors, but may inversely correlate with carotid intima medial thickness (Spearman correlation coefficient ρ = -0.268, p = 0.012). Conclusion In this 4-year prospective assessment of recently menopausal women, MHT did not significantly alter RHI when compared to placebo.

AB - Objective Endothelial dysfunction occurs early in the atherosclerotic disease process, often preceding clinical symptoms. Use of menopausal hormone treatment (MHT) to reduce cardiovascular risk is controversial. This study evaluated effects of 4 years of MHT on endothelial function in healthy, recently menopausal women. Methods Endothelial function was determined by pulse volume digital tonometry providing a reactive hyperemia index (RHI) in a subset of women enrolled in the Kronos Early Estrogen Prevention Study. RHI was measured before and annually after randomization to daily oral conjugated equine estrogen (oCEE, 0.45 mg), weekly transdermal 17β-estradiol (tE2, 50 μg) each with intermittent progesterone (200 mg daily 12 days of the month) or placebo pills and patch. Results At baseline, RHI averaged 2.39 ± 0.69 (mean ± standard deviation; n = 83), and over follow-up did not differ significantly among groups: oCEE, 2.26 ± 0.48 (n = 26); tE2, 2.26 ± 0.45 (n = 24); and placebo, 2.37 ± 0.37 (n = 33). Changes in RHI did not correlate with changes in traditional cardiovascular risk factors, but may inversely correlate with carotid intima medial thickness (Spearman correlation coefficient ρ = -0.268, p = 0.012). Conclusion In this 4-year prospective assessment of recently menopausal women, MHT did not significantly alter RHI when compared to placebo.

KW - Cardiovascular disease

KW - carotid intima-medial thickness

KW - digital tonometry

KW - endothelium

KW - estrogen

KW - menopausal symptoms

UR - http://www.scopus.com/inward/record.url?scp=84924726762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924726762&partnerID=8YFLogxK

U2 - 10.3109/13697137.2014.986719

DO - 10.3109/13697137.2014.986719

M3 - Article

VL - 18

SP - 187

EP - 197

JO - Climacteric

JF - Climacteric

SN - 1369-7137

IS - 2

ER -